Mayne Pharma has a full-service contract development and manufacturing organisation (CDMO) specialising in novel oral and topical dose forms providing pharmaceutical development, analytical testing and commercial manufacturing to clients worldwide. Our mission is to partner with clients to develop and deliver pharmaceutical products from “concept to commercialisation” to change the lives of patients around the globe:With more than 40 years of scientific expertise in developing complex oral and topical dose forms including modified release products, poorly soluble compounds and highly potent compounds, the business areas of expertise include quality pharmaceutical formulation development, first-time-in-man formulations, Phase I-III clinical trial manufacturing, analytical method development and validation services leading to commercial scale manufacturing. https://maynepharmaservices.com/resources
MYX Price at posting:
$3.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)